• Kentaro Sudo, Taketo Yamaguchi, Takeshi Ishihara, Kazuyoshi Nakamura, Taro Hara, Tadamichi Denda, Katsunobu Tawada, Toshiyuki Imagumbai, Hitoshi Araki, Mitsuhiro Sakai, Kazuo Hatano, Hiroyuki Kawakami, Takashi Uno, Hisao Ito, and Osamu Yokosuka.
• Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan. kentarosudo9@yahoo.co.jp
• Int. J. Radiat. Oncol. Biol. Phys. 2011 May 1; 80 (1): 119-25.

PurposeS-1 is an oral fluoropyrimidine derivative that has demonstrated favorable antitumor activity in patients with metastatic pancreatic cancer. The aim of this study was to evaluate safety and efficacy of S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.Methods And MaterialsPatients with histopathologically proven, unresectable, locally advanced pancreatic cancer were eligible. Radiotherapy was delivered in 1.8 Gy daily fractions to a total dose of 50.4 Gy over 5.5 weeks. S-1 was administered orally twice a day at a dose of 80 mg/m(2)/day from day 1 to 14 and 22 to 35. Two weeks after the completion of chemoradiotherapy, maintenance chemotherapy with S-1 was administered for 28 days every 6 weeks until progression.ResultsThirty-four patients were enrolled in this study. The most common Grade 3 toxicities during chemoradiotherapy were anorexia (24%) and nausea (12%). The overall response rate was 41% (95% confidence interval, 25%-58%) and overall disease control rate (partial response plus stable disease) was 97%. More than 50% decrease in serum CA 19-9 was seen in 27 of 29 evaluable patients (93%). The median progression-free survival was 8.7 months. The median overall survival and 1-year survival rate were 16.8 months and 70.6%, respectively.ConclusionsOral S-1 and concurrent radiotherapy exerted a promising antitumor activity with acceptable toxicity in patients with locally advanced pancreatic cancer. This combination therapy seems to be an attractive alternative to conventional chemoradiotherapy using 5-fluorouracil infusion.Copyright © 2011 Elsevier Inc. All rights reserved.

38 keywords...

hide…